NCT05075499View on ClinicalTrials.gov

Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab

NAUnknownINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 20, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

September 30, 2022

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

COVID-19 vaccination

Blood sample obtained before, 1 , 3 and 6 months after the intervention

Trial Locations (1)

52621

RECRUITING

Sheba Medical Center, Ramat Gan

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Sheba Medical Center

OTHER_GOV